文献速递支持与姑息治疗乳腺癌骨软组织肉瘤与黑色素瘤

DCOG LATER研究队列中儿童癌症治疗后后续恶性肿瘤的长期风险:化疗的作用

Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy.
PubMed 文献 · J Clin Oncol · 2017-05-22

荷兰DCOG LATER队列纳入1963至2001年确诊的6165例5年儿童癌症生存者,中位随访20.7年,共确认261例发生291次后续恶性肿瘤,标准化发病比为5.2(95%CI 4.6至5.8),25年累积发生率为3.9%(95%CI 3.4%至4.6%)。多柔比星暴露与全部实体癌及乳腺癌风险呈剂量依赖性增加,环磷酰胺暴露与肉瘤风险呈剂量依赖性增加。

要点

  • 5年儿童癌症生存者后续恶性肿瘤标准化发病比为5.2(95%CI 4.6至5.8),25年累积发生率为3.9%(95%CI 3.4%至4.6%)。
  • 多柔比星暴露与全部实体癌(Ptrend<.001)及乳腺癌(Ptrend<.001)风险呈剂量依赖性增加。
  • 环磷酰胺暴露与肉瘤风险呈剂量依赖性增加(Ptrend=.01)。

核心结论

  • 结果强烈提示儿童癌症生存者中多柔比星暴露增加后续实体癌和乳腺癌风险,而环磷酰胺暴露增加后续肉瘤风险。
  • 这些结果可能为未来儿童癌症治疗方案和儿童癌症生存者后续恶性肿瘤监测指南提供参考。

研究设计与样本

  • 荷兰儿童肿瘤学组儿童癌症长期效应(DCOG LATER)队列纳入1963至2001年在荷兰确诊的6165例5年儿童癌症生存者。
  • 后续恶性肿瘤通过链接荷兰癌症登记处、荷兰病理登记处及病历回顾确认。
  • 计算标准化发病比、超额绝对风险和累积发生率,并采用多变量Cox比例风险回归分析评估乳腺癌、肉瘤及全部实体癌的治疗相关风险。

主要发现

  • 自首次诊断后中位随访20.7年(范围5.0至49.8年),261例儿童癌症生存者共确认291次后续恶性肿瘤(标准化发病比5.2,95%CI 4.6至5.8;超额绝对风险20.3/10000人年)。
  • 首次诊断后25年后续恶性肿瘤累积发生率为3.9%(95%CI 3.4%至4.6%),1990年代治疗者与更早治疗者相比无明显变化。
  • 多柔比星与全部实体癌风险呈剂量依赖性增加相关(Ptrend<.001),与乳腺癌风险亦呈剂量依赖性增加相关(Ptrend<.001)。
  • 多柔比星-乳腺癌剂量反应在李-佛美尼综合征相关儿童癌症(白血病、中枢神经系统肿瘤和非尤文肉瘤)生存者中较其他癌症生存者更强(Pdifference=.008)。
  • 环磷酰胺与肉瘤风险呈剂量依赖性增加相关(Ptrend=.01)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Childhood cancer survivors (CCSs) are at increased risk for subsequent malignant neoplasms (SMNs). We evaluated the long-term risk of SMNs in a well-characterized cohort of 5-year CCSs, with a particular focus on individual chemotherapeutic agents and solid cancer risk. Methods The Dutch Childhood Cancer Oncology Group-Long-Term Effects After Childhood Cancer cohort includes 6,165 5-year CCSs diagnosed between 1963 and 2001 in the Netherlands. SMNs were identified by linkages with the Netherlands Cancer Registry, the Dutch Pathology Registry, and medical chart review. We calculated standardized incidence ratios, excess absolute risks, and cumulative incidences. Multivariable Cox proportional hazard regression analyses were used to evaluate treatment-associated risks for breast cancer, sarcoma, and all solid cancers. Results After a median follow-up of 20.7 years (range, 5.0 to 49.8 years) since first diagnosis, 291 SMNs were ascertained in 261 CCSs (standardized incidence ratio, 5.2; 95% CI, 4.6 to 5.8; excess absolute risk, 20.3/10,000 person-years). Cumulative SMN incidence at 25 years after first diagnosis was 3.9% (95% CI, 3.4% to 4.6%) and did not change noticeably among CCSs treated in the 1990s compared with those treated earlier. We found dose-dependent doxorubicin-related increased risks of all solid cancers ( Ptrend < .001) and breast cancer ( Ptrend < .001). The doxorubicin-breast cancer dose response was stronger in survivors of Li-Fraumeni syndrome-associated childhood cancers (leukemia, CNS, and non-Ewing sarcoma) versus survivors of other cancers ( Pdifference = .008). In addition, cyclophosphamide was found to increase sarcoma risk in a dose-dependent manner ( Ptrend = .01). Conclusion The results strongly suggest that doxorubicin exposure in CCSs increases the risk of subsequent solid cancers and breast cancer, whereas cyclophosphamide exposure increases the risk of subsequent sarcomas. These results may inform future childhood cancer treatment protocols and SMN surveillance guidelines for CCSs.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Teepen JC, van Leeuwen FE, Tissing WJ, et al. Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy. J Clin Oncol. 2017. PMID: 28530852. doi:10.1200/JCO.2016.71.6902

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。